The Latest Breaking News from FDA

Alnylam stock skidded Monday after the FDA rejected its drug, Onpattro, as a treatment for patients with a heart disease.

Bristol Myers Squibb offered to buy Mirati Therapeutics for up to $5.8 billion, but MRTX stock tumbled on the lowball price.

Though side effects from Ozempic are rare, as usage rises some side effects are becoming more apparent

Five former inmates at an Arkansas county jail have settled their lawsuit against a doctor who they say gave them ivermectin without their consent to treat COVID-19

With an aging population worldwide, the rising prevalence of chronic diseases, and numerous technological advancements, the medical device sector stands primed for considerable growth and expansion. The industry tailwinds should benefit medical device stocks T2 Biosystems (TTOO) and IDEXX Laboratories (IDXX). However, which stock is poised for better gains this…

The Food and Drug Administration signed off on Novavax's updated Covid booster late Tuesday, and NVAX stock surged just before the close.

More than 60 primary schoolchildren have been taken to hospital after eating cannabis-laced sweets in Jamaica.

Doctors need to get into the AI oversight game–before it's too late.

In one form or another, all those questions are back on the table this term — mainly to take a second look at appeals from the Fifth Circuit Court of Appeals, which covers Texas and parts the South.

Sydney-based Cyclopharm is preparing to send hundreds of its generators to the US for use in diagnosing pulmonary embolisms after receiving regulatory approval.

Psychedelic retreats are becoming more popular as people wait for FDA approval. But do they work?